25419179|t|Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
25419179|a|BACKGROUND: Diabetes mellitus (DM) is associated with poor outcome after surgery. The prevalence of DM in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a patient with DM in the operating room on a daily basis. Despite an abundance of published glucose lowering protocols and the known negative outcomes associated with perioperative hyperglycaemia in DM, there is no evidence regarding the optimal intraoperative glucose lowering treatment. In addition, protocol adherence is usually low and protocol targets are not simply met. Recently, incretins have been introduced to lower blood glucose. The main hormone of the incretin system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner, resulting in glucose lowering action with a low incidence of hypoglycaemia. We set out to determine the optimal intraoperative treatment algorithm to lower glucose in patients with DM type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GPL-1 (liragludite, LG) treatment. METHODS/DESIGN: This is a multicentre randomised open label trial in patients with DM type 2 undergoing non-cardiac surgery. Patients are randomly assigned to one of three study arms; intraoperative glucose-insulin-potassium infusion (GIK), intraoperative sliding-scale insulin boluses (BR) or GPL-1 pre-treatment with liraglutide (LG). Capillary glucose will be measured every hour. If necessary, in all study arms glucose will be adjusted with an intravenous bolus of insulin. Researchers, care givers and patients will not be blinded for the assigned treatment. The main outcome measure is the difference in median glucose between the three study arms at 1 hour postoperatively. We will include 315 patients, which gives us a 90% power to detect a 1 mmol l(-1) difference in glucose between the study arms. DISCUSSION: The PILGRIM trial started in January 2014 and will provide relevant information on the perioperative use of GLP-1 agonists and the optimal intraoperative treatment algorithm in patients with diabetes mellitus type 2. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02036372.
25419179	84	91	insulin	Gene	3630
25419179	100	105	GLP-1	Gene	2641
25419179	119	127	diabetes	Disease	MESH:D003920
25419179	155	172	Diabetes mellitus	Disease	MESH:D003920
25419179	174	176	DM	Disease	MESH:D003920
25419179	243	245	DM	Disease	MESH:D003920
25419179	262	270	patients	Species	9606
25419179	337	344	patient	Species	9606
25419179	350	352	DM	Disease	MESH:D003920
25419179	427	434	glucose	Chemical	MESH:D005947
25419179	516	530	hyperglycaemia	Disease	
25419179	534	536	DM	Disease	MESH:D003920
25419179	596	603	glucose	Chemical	MESH:D005947
25419179	762	775	blood glucose	Chemical	MESH:D001786
25419179	820	843	glucagon-like peptide-1	Gene	2641
25419179	845	850	GLP-1	Gene	2641
25419179	853	858	GLP-1	Gene	2641
25419179	869	876	insulin	Gene	3630
25419179	891	899	glucagon	Gene	2641
25419179	915	922	glucose	Chemical	MESH:D005947
25419179	954	961	glucose	Chemical	MESH:D005947
25419179	1002	1015	hypoglycaemia	Disease	
25419179	1097	1104	glucose	Chemical	MESH:D005947
25419179	1108	1116	patients	Species	9606
25419179	1122	1131	DM type 2	Disease	MESH:D003924
25419179	1189	1196	glucose	Chemical	MESH:D005947
25419179	1197	1204	insulin	Gene	3630
25419179	1205	1214	potassium	Chemical	MESH:D011188
25419179	1231	1238	insulin	Gene	3630
25419179	1262	1267	GPL-1	Chemical	-
25419179	1269	1280	liragludite	Chemical	-
25419179	1366	1374	patients	Species	9606
25419179	1380	1389	DM type 2	Disease	MESH:D003924
25419179	1422	1430	Patients	Species	9606
25419179	1496	1503	glucose	Chemical	MESH:D005947
25419179	1504	1511	insulin	Gene	3630
25419179	1512	1521	potassium	Chemical	MESH:D011188
25419179	1567	1574	insulin	Gene	3630
25419179	1644	1651	glucose	Chemical	MESH:D005947
25419179	1713	1720	glucose	Chemical	MESH:D005947
25419179	1767	1774	insulin	Gene	3630
25419179	1805	1813	patients	Species	9606
25419179	1915	1922	glucose	Chemical	MESH:D005947
25419179	1999	2007	patients	Species	9606
25419179	2075	2082	glucose	Chemical	MESH:D005947
25419179	2227	2232	GLP-1	Gene	2641
25419179	2296	2304	patients	Species	9606
25419179	2310	2334	diabetes mellitus type 2	Disease	MESH:D003924
25419179	Negative_Correlation	MESH:D011188	MESH:D003924
25419179	Negative_Correlation	MESH:D001786	2641
25419179	Negative_Correlation	MESH:D011188	2641
25419179	Association	MESH:D005947	3630
25419179	Negative_Correlation	2641	3630
25419179	Negative_Correlation	MESH:D003920	2641
25419179	Negative_Correlation	MESH:D003924	2641
25419179	Negative_Correlation	MESH:D005947	2641
25419179	Negative_Correlation	MESH:D005947	MESH:D011188

